For the year ending 2025-12-31, PTHS had $17,510K increase in cash & cash equivalents over the period. -$22,689K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -43,319 |
| Accretion of interest for royalty obligations | 2,397 |
| Change in fair value of convertible note | -14,984 |
| Depreciation of property and equipment | 729 |
| Amortization of intangible assets | 1,556 |
| Impairment of intangible assets | 285 |
| Amortization of debt discount | 259 |
| Lease amortization expense | 74 |
| Stock-based compensation | 5,461 |
| Inventory write-off | 1,055 |
| Gain on default judgment | 0 |
| Accounts receivable | 8,810 |
| Inventory | -1,778 |
| Prepaid expenses | 880 |
| Operating lease right-of-use assets | -345 |
| Accounts payable | 1,356 |
| Accrued expenses | 6,163 |
| Contingent consideration | 2,200 |
| Operating lease liabilities | -282 |
| Deferred revenue | -589 |
| Deferred income tax | 7,387 |
| Other assets and liabilities | -35 |
| Net cash used in operating activities | -22,590 |
| Purchases of property and equipment | 99 |
| Assets acquisition-Xepi Acquisition | 6,080 |
| Assets acquisition-XEGLYZEAsset Purchase Agreement | 1,818 |
| Acquisition of lnhc, inc | 2,761 |
| Net cash used in investing activities | -5,236 |
| Proceeds from pipe, net | 27,384 |
| Proceeds from stock option exercises | 206 |
| Proceeds from convertible note | 17,898 |
| Proceeds from loan payable, net of debt discount | 693 |
| Payment of loan payable, net of debt discount | 845 |
| Common stock issued for cash | 0 |
| Rescission of common stock | 0 |
| Repurchase of common stock under stock repurchase plan | 0 |
| Shares issued for cash under equity line of credit | 0 |
| Net cash provided by financing activities | 45,336 |
| Net increase in cash and cash equivalents | 17,510 |
| Cash, cash equivalents and restricted cash as of beginning of period | 513 |
| Cash, cash equivalents and restricted cash as of end of period | 18,023 |
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)